hairy cell leukaemia and other lymphoid malignancies . Br J Haematol 2011 ; 155 : 609 – 612 . 10. Tiacci E Trifonov V Schiavoni G . BRAF mutations in hairy-cell leukemia . N Engl J Med 2011 ; 364 : 2305 – 2315 . 11. Andrulis
Search Results
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar
Katherine M. Bever and Dung T. Le
associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes . Mod Pathol 2016 ; 29 : 1104 – 1112 . 11. Llosa NJ Cruise M Tam A . The vigorous immune microenvironment of
Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes
papillary thyroid cancer who have ALK gene fusions; however, these ALK gene fusions are rarely reported in patients with ATC. 97 – 100 BRAF mutations have been reported in patients with ATC. 35 , 101 – 103 Individual Disclosures of the NCCN
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
; 27 ( Suppl ): Abstract 4001 . 33. Hutchins G Southward K Handley K . Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer . J Clin Oncol 2011 ; 29 : 1261 – 1270
Kristen Keon Ciombor and Tanios Bekaii-Saab
leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 56. Tveit KM Guren T Glimelius B . Phase III
Jean L. Grem
irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 50. Douillard JY
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
testing using a validated test(s) that assesses a minimum of the following potential genetic variants: ALK rearrangements (category 1), BRAF mutations, EGFR mutations (category 1), METex14 skipping mutation s , NTRK1/2/3 gene fusions, RET
Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow
hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis . Int J Gynecol Pathol 2012 ; 31 : 195 – 205 . 71. McConechy MK Talhouk A Li-Chang HH . Detection of DNA mismatch repair (MMR) deficiencies
Cesar A. Santa-Maria and Rita Nanda
without BRAF mutation . N Engl J Med 2015 ; 372 : 320 – 330 . 7. Brahmer J Reckamp KL Baas P . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer . N Engl J Med 2015 ; 373 : 123 – 135 . 8. Perou CM
Jessica S.W. Borgers, Richard P. Tobin, Robert J. Torphy, Victoria M. Vorwald, Robert J. Van Gulick, Carol M. Amato, Dasha T. Cogswell, Tugs-Saikhan Chimed, Kasey L. Couts, Adrie Van Bokhoven, Christopher D. Raeburn, Karl D. Lewis, Joshua Wisell, Martin D. McCarter, Rao R. Mushtaq, and William A. Robinson
mutations in patients with AGM (n=1; 5%) compared with those without (n=13; 24%) ( P =.095) ( Table 1 ). BRAF mutations were present in 45% and c-KIT mutations in 2% of the patients with AGM compared with 39% and 6%, respectively, in those without
